Pharmacokinetics of vinorelbine in patients with liver metastases

Clinical Pharmacology and Therapeutics

Volumn 59, Issue 1, 1996, Pages 32-40

  Robieux, Isabelle ^a   Sorio, Roberto ^b   Borsatti, Eugenio ^b   Cannizzaro, Renato ^b   Vitali, Vinicio ^b   Aita, Paola ^b   Freschi, Andrea ^b   Galligioni, Enzo ^b   Monfardini, Silvio ^b  

^a CENTRO DI RIFERIMENTO ONCOLOGICO   (Italy)

^b NONE

Author keywords

[No Author keywords available]

Indexed keywords

AMITRIPTYLINE; LORAZEPAM; NAVELBINE; OMEPRAZOLE; PHENOBARBITAL; RANITIDINE; TEMAZEPAM;

ADULT; AGED; ARTICLE; BREAST CANCER; CLINICAL ARTICLE; CONTROLLED STUDY; DRUG BLOOD LEVEL; DRUG CLEARANCE; DRUG ELIMINATION; DRUG HALF LIFE; DRUG METABOLISM; FEMALE; HUMAN; INTRAVENOUS DRUG ADMINISTRATION; LIVER FUNCTION TEST; LIVER METASTASIS; PRIORITY JOURNAL;

ADULT; AGED; AGED, 80 AND OVER; ANTINEOPLASTIC AGENTS, PHYTOGENIC; BREAST NEOPLASMS; FEMALE; HALF-LIFE; HUMANS; LIDOCAINE; LIVER FUNCTION TESTS; LIVER NEOPLASMS; MIDDLE AGED; VINBLASTINE;

EID: 0030042231     PISSN: 00099236     EISSN: None     Source Type: Journal    
DOI: 10.1016/S0009-9236(96)90021-1     Document Type: Article

References (35)

1. Marty M, Extra JM, Dieras V, Giacchetti S, Ohana S, Espie M. A review of antitumor activity of vinorelbine in breast cancer. Drugs 1992;44:29-35.
2. Pinedo HM, van Groeningen CJ. Vinorelbine: a horse of a different color. J Clin Oncol 1994;12:1745-7.
3. Spielmann M, Dorval T, Turpin F, et al. Phase II trial of vinorelbine/doxorubicine as first line therapy of advanced breast cancer. J Clin Oncol 1994;12:1764-70.
4. Zhou XJ, Rahmani R. Precinical and clinical pharmacology of vinca alkaloids. Drugs 1992;44(suppl):1-16.
5. Van der Berg HW, Desai ZR, Wilson R, et al. The pharmacokinetics of vincristine in man: reduced clearance associated with raised serum alkaline phosphatase and dose limited elimination. Cancer Chemother Pharmacol 1982;8:215-9.
6. Navelbine package insert: labeling information for Italy; precaution for use. Pierre Fabre Pharma Srl, 1994.
7. Reynolds JEF, ed. Martindale: the extra pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993: 506-7.
8. Oellerich M, Burdelski M, Ringe B, et al. Lignocaine metabolite formation as a measure of pre-transplant liver function. Lancet 1989;1:640-2.
9. Reichen J. MEGX test in hepatology: the long sought ultimate quantitative liver function test? J Hepatol 1993;19:4-7.
10. Stangl R, Altendorf A, Charnley R, Scheele J. Factors influencing the natural history of colorectal liver metastases. Lancet 1994;343:1405-10.
11. Bengston G, Carlsson G, Hafstrom L, Jonsson PE. Natural history of patients with untreated liver metastases. Am J Surg 1981;141:586-9.
12. Gennari L, Doci R, Bozzetti F, Veronesi U. Proposal for a clinical classification of liver metastases. Tumori 1982;68:443-9.
13. Debal V, Morjani H, Millot JM, Angiboust JF, Gourdier B, Manfait M. Determination of vinorelbine (Navelbine) in tumor cells by high performance liquid chromatography. J Chromatogr 1992;581:93-9.
14. Robieux I, Vitali V, Aita P, Freschi A, Lazzarini R, Sorio R. Sensitive HPLC method with fluorescence detection for measurement of vinorelbine plasma concentration. J Chromatogr [In press].
15. Gibaldi M, Perrier D. Noncompartmental analysis based on statistical moment theory in pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982:409-17.
16. Khayat D, Covelli A, Variol P, Benhamouda A, Jacques C, Bugat R. Phase I and pharmacologic study of intravenous vinorelbine in patients with solid tumors [Abstract]. J Clin Oncol 1995;14:469.
17. Jehl F, Quoix E, Leveque D, et al. Pharmacokinetic and preliminary metabolic fate of Navelbine in Humans as determined by HPLC. Cancer Res 1991;51: 2073-6.
18. Krikorian A, Rahmani R, Bromet M, Bore P, Cano JP. Pharmacokinetics and metabolism of navelbine. Semin Oncol 1989;2:21-5.
19. Gibaldi M, Perrier D. Kinetics of pharmacologic response in pharmacokinetics. 2nd ed. New York: Marcel Dekker, 1982:221-69.
20. Koyabashi K, Ratain MJ. Individualizing dosing of cancer chemotherapy. Semin Oncol 1993;33:1-9.
21. Ratain MJ, Schilsky RL, Conely BA, Egorin MJ. Pharmacodynamics in cancer therapy. J Clin Oncol 1990;8:1739-53.
22. Piscitelli SC, Rotvold KA, Rushing DA, Tewksbury DA. Pharmacokinetics and pharmacodynamics of doxorubicin in patients with small cell lung cancer. CLIN PHARMACOL THER 1993;53:555-61.
23. Desai ZR, Van der Bergh HW, Bridges JM, et al. Can severe vincristine neurotoxicity be prevented? Cancer Chemother Pharmacol 1982;8:211-4.
24. Rowinsky EK, Noe DA, Trump DL, et al. Pharmacokinetic, bioavailability and feasibility study of oral vinorelbine in patients with solid tumors. J Clin Oncol 1994;12:1754-63.
25. Marquet P, Lachatre G, Debord J, Eichler B, Bonnaud F, Nicot G. Pharmacokinetics of vinorelbine in man. Eur J Clin Pharmacol 1992;42:545-7.
26. Lauterburg BH, Preisig R. Quantitation of liver function. In: McIntyre N, ed. Oxford Textbook of clinical hepatology. Oxford: Oxford University Press, 1991: 309-14.
27. Bargetzi MJ, Aoyama T, Gonzales FJ, Meyer UA. Lidocaine metabolism in human liver microsomes by cytochrome P450 IIIA4. CLIN PHARMACOL THER 1989; 46:521-7.
28. Oellerich M, Burdelski M, Lantz HU, Schulz M, Schmidt F, Hermann H. Lidocaine metabolite formation as a measure of liver function in patients with cirrhosis. Ther Drug Monit 1990;12:219-26.
29. Shiffman ML, Luketic V, Sanyal AJ, et al. Hepatic lidocaine metabolism and liver histology in patients with chronic hepatitis and cirrhosis. Hepatology 1994; 19:933-9.
30. Gremse DA, A-Kader H, Shroeder TJ, Balistreri WF. Assessment of lidocaine metabolite formation as a quantitative liver function test in children. Hepatology 1990;12:565-9.
31. Cannizzro R, Robieux I, Sorio R, et al. Quantitative liver function by monoethylglycinexylidide (MEGX) test in liver metastases. Gastroenterology 1995;108:A454.
32. Reynolds JEF, ed. Martindale: the extra pharmacopeia. 30th ed. London: Pharmaceutical Press, 1993:901.
33. Gilman AG, ed. The pharmacological basis of therapeutics. 8th ed. New York: Pergamon Press, 1990:71.
34. Anderson T. Omeprazole drug interaction studies. Clin Pharmacokinet 1991;21:195-212.
35. Pon SM. Effects of tricyclic antidepressant on drug metabolism. CLIN PHARMACOL THER 1975;13:351-6.